Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.

Abstract

Neuroendocrine tumors are heterogeneous, rare malignancies that arise most commonly in the gastrointestinal tract and pancreas. They often secrete vasoactive substances resulting in carcinoid syndrome and the tumor cells exclusively express somatostatin receptors. Octreotide and lanreotide are the two synthetic somatostatin analogs used for the control of carcinoid symptoms and tumor progression in advanced inoperable disease. Recent pivotal trials (PROMID and CLARINET studies) established their antitumor activity. We discuss the available data to support their use as symptom controlling and antiproliferative agents. This article also reviews the guidelines (National Comprehensive Cancer Network and North American Neuro Endocrine Tumor Society), cost-analysis (suggesting the cost-effectiveness of lanreotide autogel compared to higher doses of octreotide long acting release formulation in refractory patients), and future directions of somatostatin analogs in the management of patients refractory to conventional doses of octreotide and lanreotide.

• Authors: Venkata K Pokuri, Mei Ka Fong, Renuka Iyer
• Journal: Current oncology reports (Curr Oncol Rep) Vol. 18 Issue 1 Pg. 7 (Jan 2016) ISSN: 1534-6269 [Electronic] United States
• PMID: 26743514 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents, Hormonal
• Peptides, Cyclic
• lanreotide
• Somatostatin
• Octreotide

Topics

• Antineoplastic Agents, Hormonal (therapeutic use)
• Humans
• Intestinal Neoplasms (drug therapy, mortality)
• Neuroendocrine Tumors (drug therapy, mortality)
• Octreotide (therapeutic use)
• Pancreatic Neoplasms (drug therapy, mortality)
• Peptides, Cyclic (therapeutic use)
• Prognosis
• Somatostatin (analogs & derivatives, therapeutic use)
• Stomach Neoplasms (drug therapy, mortality)
• Treatment Outcome